FormBlends Launches Comprehensive GLP-1 and Peptide Intelligence Platform

New platform features 7,282 provider profiles, 100 clinical research reports, and interactive health tools

Apr. 9, 2026 at 7:08am by Ben Kaplan

Got story updates? Submit your updates here. ›

An extreme close-up X-ray photograph revealing the internal structure of a GLP-1 medication capsule, with the ghostly outlines of the capsule and its contents glowing against a dark background, conceptually illustrating the platform's focus on providing detailed clinical information about these therapies.FormBlends' comprehensive GLP-1 and peptide therapy platform aims to provide patients with transparent, evidence-based information to navigate the rapidly growing market for these treatments.San Francisco Today

FormBlends, a health technology platform focused on GLP-1 weight loss results and weight management provider directory listings, has announced the completion of a major platform expansion that positions it as the most comprehensive consumer intelligence resource for prescription weight management medications in the United States.

Why it matters

As the $45 billion GLP-1 market accelerates toward $122 billion by 2030, FormBlends is building the definitive consumer resource for evidence-based medication information, provider transparency, and clinical education to address an information crisis in the fastest-growing drug category.

The details

The platform now features 7,282 individually profiled provider listings across all 50 states, 100 physician-reviewed clinical research reports, 17 interactive health tools, and a clinical education library covering every major GLP-1 and peptide therapy on the market. FormBlends aims to close the widening gap between what consumers need to know and what they can reliably find online about these fast-growing treatments.

  • FormBlends announced the platform expansion on April 9, 2026.
  • The global GLP-1 receptor agonist market reached $45.3 billion in 2025 and is projected to hit $122.3 billion by 2030.
  • Beginning July 1, 2026, Medicare will cover select GLP-1 receptor agonist medications for weight management at a $50 per month copay through the new 'Medicare GLP-1 Bridge' program.

The players

FormBlends

A health technology platform focused on GLP-1 weight loss results and weight management provider directory listings.

Got photos? Submit your photos here. ›

What they’re saying

“Patients are navigating an information environment where marketing is frequently disguised as medical advice. The gap between what consumers need to know and what they can reliably find online is widening every month. We built this platform to close that gap with physician-reviewed, evidence-based clinical content.”

— FormBlends Spokesperson

“We are not building a company that happens to have health content. We are building the most trusted clinical resource on the internet for GLP-1 and peptide therapy information, backed by peer-reviewed research and transparent provider data.”

— FormBlends Spokesperson

What’s next

The FormBlends platform is available now at formblends.com. All educational content, research reports, interactive tools, and provider directory listings are free to access. Patients interested in exploring whether physician-supervised treatment may be appropriate for their circumstances can begin with a free health assessment.

The takeaway

FormBlends is building the definitive consumer resource for evidence-based GLP-1 and peptide therapy information, addressing an information crisis in the fastest-growing drug category as the $45 billion GLP-1 market accelerates toward $122 billion by 2030.